Learn Why Dsm International B.V. Purchased Amyris, Inc Stake?

July 17, 2017 - By Hazel Jackson

 Learn Why Dsm International B.V. Purchased Amyris, Inc Stake?

Investors sentiment increased to 0.92 in 2016 Q4. Its up 0.23, from 0.69 in 2016Q3. It increased, as 1 investors sold Amyris Inc shares while 11 reduced holdings. 5 funds opened positions while 6 raised stakes. 77.23 million shares or 7.17% less from 83.20 million shares in 2016Q3 were reported.

Blackrock Advsrs owns 0% invested in Amyris Inc (NASDAQ:AMRS) for 8,820 shares. The New York-based Jane Street Group Inc Ltd Liability Company has invested 0% in Amyris Inc (NASDAQ:AMRS). Vanguard Group Inc Inc Inc stated it has 3.10 million shares or 0% of all its holdings. Royal Retail Bank Of Canada reported 1,000 shares or 0% of all its holdings. 46,064 are held by Morgan Stanley. Kbc Gp Nv stated it has 0% of its portfolio in Amyris Inc (NASDAQ:AMRS). Bridgeway Capital Mngmt holds 0% or 50,800 shares. California Employees Retirement Sys has invested 0% in Amyris Inc (NASDAQ:AMRS). State Bank Of America Corp De reported 500 shares stake. Gofen Glossberg Limited Co Il holds 40,000 shares. Goldman Sachs Grp Incorporated reported 16,603 shares stake. Geode Cap Mgmt Limited Liability Co invested 0% in Amyris Inc (NASDAQ:AMRS). Manufacturers Life Comm The has 0% invested in Amyris Inc (NASDAQ:AMRS). Carl Domino holds 0.11% or 147,000 shares in its portfolio. Sg Americas Secs Lc invested in 0% or 15,300 shares.

The New Dsm International B.V. Holding in Amyris, Inc

Dsm International B.V. reported SC 13D form with the SEC for Amyris, Inc. Access it here: 000114036117027997. As reported by Dsm International B.V., the filler owns 27.7% or 7,936,232 shares of the Materials–company.

Amyris, Inc stake is new for [reportingPerson]. Date of activity: July 7, 2017. This shows Dsm International B.V.’s positive view for Amyris, Inc.

Reasons Why Dsm International B.V. Bought – Amyris, Inc Stock

Purpose of Transaction

Securities Purchase Agreement

On May 8, 2017, the Issuer, DSM International and certain other investors entered into Securities Purchase Agreement (the “Purchase Agreement”), for the issuance and sale of shares of the Issuer’s Series A 17.38% Convertible Preferred Stock (the “Series A Preferred Stock”), shares of the Issuer’s Series B 17.38% Convertible Preferred Stock, (the “Series B Preferred Stock”), two series of warrants to purchase shares of the Issuer’s Common Stock at exercise prices of $7.80 per share and $9.30 per share (the “Cash Warrants”), and warrants to purchase additional shares of Common Stock in the event the Issuer undertakes certain dilutive transactions (the “Dilution Warrant” and, together with the Cash Warrants, the “Warrants”).

On July 7, 2017, the Issuer’s stockholders approved (the “Stockholder Approval”) the issuance of shares of Common Stock upon the conversion of the SeriesB Preferred Stock and Warrants sold pursuant to the Purchase Agreement. Following the Stockholder Approval, each share of Series B Preferred Stock is convertible at any time at the option of the holder into approximately 158.7 shares of Common Stock, subject to certain adjustments. Also following the Stockholder Approval, the Cash Warrants became immediately exercisable.

The Dilution Warrant held by DSM International gives DSM International the right to purchase a number of shares of Common Stock, at a price of $0.0001 per share, sufficient to provide it with full-ratchet anti-dilution protection for any issuance by the Issuer of equity or equity-linked securities during the three year period following Closing at a per share price (including any conversion or exercise price, if applicable) less than $6.30 per share.

Standstill Requirement

Pursuant to the terms of the Purchase Agreement, from Closing until three months after no Designated Director (as defined below) serves on the Board of the Issuer, the Reporting Persons shall not directly or indirectly, without prior consent of the Issuer, (i) acquire or agree to acquire, tender or exchange offer beneficial ownership of additional voting securities or convertible securities after the Closing that would result in the Reporting Persons beneficially owning more than 33.0% of the Issuer’s voting securities; (ii) make or participate in any “solicitation” of “proxies” to vote the Issuer’s voting securities or to advise or influence any person with respect to the voting of such securities or deposit any such securities in any voting trust; (iii) make any public announcement of a proposal with respect to any extraordinary transaction involving the Reporting Persons and the Issuer; (iv) effect or seek to effect any recapitalization, reclassification, liquidating or dissolution of the Issuer; (v) publicly disclose any intention, plan or arrangement by Reporting Persons regarding the possibility of any of the events described in clauses (i) through (iv) above; (vi) knowingly take any action that would require the Issuer or the Reporting Persons under applicable laws or exchange rules to make a public announcement regarding any of the events described in clauses (i) through (iv) above; and

CUSIP No. 03236M101

13D

Page

5

of 8 Pages

(vii) enter into any discussion, negotiations, agreements or understanding with any other third party with respect to the foregoing.

Registration Rights

Pursuant to the Purchase Agreement, within 30 calendar days of the date of the Stockholder Approval, the Issuer has agreed to file a registration statement on Form S-3 (or other appropriate form if the Issuer is not then S-3 eligible) providing for the resale by DSM International and the other investors of the shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Cash Warrants. The Issuer has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days following the Closing and commercially reasonable efforts to keep such registration statement effective at all times until (i) no party to the Purchase Agreement owns any shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Cash Warrants or (ii) the shares of Common Stock issuable upon conversion or exercise of the Series B Preferred Stock and Cash Warrants are eligible for resale under Rule 144 without regard to volume limitations.

Stockholder Agreement

On May 11, 2017, the Issuer and DSM International entered in to a Stockholder Agreement (the “Stockholder Agreement”), pursuant which the Issuer granted DSM International the right, subject to certain restrictions, to designate one director selected by DSM International (the “Designated Director”) to the Issuer’s Board of Directors (the “Board”). DSM International selected Philip Eykerman as the Designated Director and, on May 18, 2017, the Board appointed Mr. Eykerman to serve as a director.

Pursuant to the terms of the Stockholder Agreement, the Issuer has agreed, consistent with the Board’s fiduciary duties, to cause the Designated Director to be re-nominated in the future; provided, that DSM International will cease to have the right to designate any Designated Director at such time as DSM International or its affiliates hold less than 4.5% of the outstanding Common Stock. In addition, for as long as there is a Designated Director serving on the Board, the Issuer has agreed not to engage in certain commercial or financial transactions or arrangements without the consent of any then-serving Designated Director. The Stockholder Agreement also grants DSM International certain pre-emptive rights to purchase additional shares of capital stock of the Issuer in connection with a sale of equity or equity-linked securities by the Issuer in a capital raising transaction for cash, subject to certain exceptions, to maintain its proportionate ownership percentage in the Issuer.

CUSIP No. 03236M101

13D

Page

6

of 8 Pages

General

The Reporting Persons acquired the securities described in this Statement for investment purposes and they intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

Subject to the limitations in the Purchase Agreement and Stockholder Agreement, the Reporting Persons may, at any time and from time to time, acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, subject to the limitations in the Purchase Agreement, the Reporting Persons or their designee(s) to the Board may engage in discussions with management, the Board, and shareholders of the Issuer and other relevant parties or encourage such persons to consider or explore extraordinary corporate transactions, such as: a merger; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer’s business or corporate structure, including changes in management or the composition of the Board.

Other than as described above, none of the Reporting Persons currently has any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

Amyris, Inc Institutional Sentiment

Filings show 45 investors own Amyris, Inc. The ownership in Q3 2015 is low, at 315.44 % of the outstanding shares. This is increased by 38337531. 62489443 were owned by these investors. 5 funds opened new Amyris, Inc stakes, 12 increased positions. There were 15 that closed positions and 12 reduced them.

Concourse Capital Management Llc is an investor bullish on Amyris, Inc, owning 43110 shares as of Q3 2015 for 0.04% of its portfolio. Tpg Group Holdings Sbs Advisors Inc owns 3978660 shares or 0.04% of its portfolio. CA Connective Capital Management Llc have 3.96% of its portfolio for 961537 shares. Further, Temasek Holdings Private Ltd reported stake worth 0.81% of its portfolio. The CA First Republic Investment Management Inc owns 30000 shares. Amyris, Inc is less than 0.01% of its portfolio.

Business Profile

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

SEC Form 13D.

The stock increased 7.67% or $0.26 on July 17, reaching $3.65. About 206,493 shares traded. Amyris Inc (NASDAQ:AMRS) has declined 47.38% since July 18, 2016 and is downtrending. It has underperformed by 64.08% the S&P500.

Amyris, Inc. is an integrated industrial biotechnology company. The company has market cap of $72.94 million. The Firm is engaged in research and development and sales of fuels and farnesene-derived products. It currently has negative earnings. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances , solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Amyris Inc (NASDAQ:AMRS) Ratings Coverage

Among 3 analysts covering Amyris Inc (NASDAQ:AMRS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Amyris Inc has $1500 highest and $2 lowest target. $7’s average target is 91.78% above currents $3.65 stock price. Amyris Inc had 4 analyst reports since November 10, 2015 according to SRatingsIntel. Cowen & Co maintained Amyris Inc (NASDAQ:AMRS) rating on Thursday, March 10. Cowen & Co has “Market Perform” rating and $2 target. The company was maintained on Wednesday, June 7 by H.C. Wainwright. Rodman & Renshaw initiated Amyris Inc (NASDAQ:AMRS) rating on Tuesday, November 10. Rodman & Renshaw has “Buy” rating and $4 target. On Tuesday, November 10 the stock rating was initiated by H.C. Wainwright with “Buy”.

More notable recent Amyris Inc (NASDAQ:AMRS) news were published by: Seekingalpha.com which released: “Amyris – The Correction Is Over” on April 12, 2017, also Seekingalpha.com with their article: “Amyris: Entering Robust Revenue Ramp, Initiate Buy Rating” published on January 03, 2017, Globenewswire.com published: “Amyris to Announce First Quarter 2017 Financial Results on Monday, May 15, 2017” on May 09, 2017. More interesting news about Amyris Inc (NASDAQ:AMRS) were released by: Seekingalpha.com and their article: “Amyris -38% on planned equity offerings” published on May 08, 2017 as well as Globenewswire.com‘s news article titled: “Amyris Announces Much Better Than Expected Sales Of Farnesene To Meet …” with publication date: May 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.